

Ambrogio Orlando

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4932356/ambrogio-orlando-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

2,254
citations

23
h-index

45
g-index

95
ext. papers

2,723
ext. citations

4.7
avg, IF

4.79
L-index

#	Paper	IF	Citations
90	Ozanimod for Ulcerative Colitis.. <i>New England Journal of Medicine</i> , 2022 , 386, 194	59.2	2
89	Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.. <i>Inflammatory Bowel Diseases</i> , 2022 ,	4.5	1
88	SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 3041-3049	4	1
87	COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD PatientsSAssociation. <i>Inflammatory Bowel Diseases</i> , 2021 ,	4.5	9
86	Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?. <i>Gastroenterology</i> , 2021 , 160, 1877-1878	13.3	6
85	A propensity score weighted comparison of vedolizumab and adalimumab in CrohnS disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 105-111	4	7
84	The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 182-189	4.5	19
83	Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211010668	4.7	10
82	Ustekinumab in CrohnS disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases. <i>JGH Open</i> , 2021 , 5, 364-370	1.8	7
81	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , 2021 ,	5.4	2
80	Letter: propensity score-handle with care. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 53, 360-361	6.1	1
79	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020 , 52, 1461-1466	3.3	5
78	Herpes Zoster Eruption During Vedolizumab Therapy: A Simple Coincidence or More?. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, e51-e52	4.5	0
77	Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study. <i>Inflammatory Bowel Diseases</i> , 2020 , 26, 450-459	4.5	20
76	Persistence on Anti-Tumour Necrosis Factor Therapy in OlderIPatients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020 , 37, 383-392	4.7	12
75	Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. <i>Digestive and Liver Disease</i> , 2020 , 52, 44-50	3.3	7
74	Effectiveness and safety of Ustekinumab for the treatment of CrohnS disease in real-life experiences: a meta-analysis of observational studies. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 193-203	5.4	16

73	The VERSIFY Trial: What About Ultrasound Assessment?. <i>Gastroenterology</i> , 2020 , 158, 1176-1177	13.3	
72	Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality. <i>Digestive and Liver Disease</i> , 2020 , 52, 506-515	3.3	9
71	Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020 , 52, 1304-1309	3.3	5
70	Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthritis: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1381-1384	5.4	2
69	Ustekinumab for treating ulcerative colitis: an expert opinion. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1321-1329	5.4	2
68	Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study. <i>United European Gastroenterology Journal</i> , 2020 , 8, 1045-1055	5.3	8
67	COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. <i>Digestive and Liver Disease</i> , 2020 , 52, 1222-1227	3.3	26
66	Effectiveness and safety of biologics in pediatric inflammatory bowel disease: Real-life data from the Sicilian Network. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020 , 44, 223-229	2.4	5
65	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020 , 101, 433-440	3.6	8
64	Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. <i>Scandinavian Journal of Gastroenterology</i> , 2019 , 54, 1102-1106	2.4	6
63	Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. <i>Gastroenterology Research and Practice</i> , 2019 , 2019, 3108025	2	4
62	Inflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?. <i>Clinical Drug Investigation</i> , 2019 , 39, 799-803	3.2	15
61	Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. <i>Digestive and Liver Disease</i> , 2019 , 51, 1270-1274	3.3	4
60	Barriers to anti-TNFalpha prescription among Italian physicians managing inflammatory bowel disease. <i>GastroHep</i> , 2019 , 1, 93-99	1	2
59	Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review. <i>Digestive and Liver Disease</i> , 2019 , 51, 613-620	3.3	8
58	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019 , 51, 632-639	3.3	22
57	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 1805-1812	4.5	19
56	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 568-579	4.5	35

55	Letter: psoriasiform eruption during vedolizumab therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 342-343	6.1	1
54	Anti-TNF combination therapy in inflammatory bowel disease: de novo or selective?. <i>Minerva Gastroenterologica E Dietologica</i> , 2019 , 65, 291-297	1.6	2
53	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 987-997	4.5	10
52	Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 234-236	6.1	8
51	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 89-98	5.4	23
50	Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2019 , 51, 510-515	3.3	9
49	Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 640-647	3.3	7
48	Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019 , 47, 409-415	5.8	3
47	Unmet needs of Italian physicians managing patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2019 , 51, 212-217	3.3	5
46	A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease. <i>Journal of Crohns and Colitis</i> , 2019 , 13, 209-217	1.5	19
45	Risk of Pneumonia Caused by Pneumocystis jiroveci in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 571-572	6.9	6
44	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018 , 35, 545-562	4.1	6
43	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 394-401	4.5	9
42	How clinicians and pathologists interact concerning inflammatory bowel disease in Italy: An IG-IBD survey. <i>Digestive and Liver Disease</i> , 2018 , 50, 734-736	3.3	2
41	Ustekinumab in the management of Crohn's disease: Expert opinion. <i>Digestive and Liver Disease</i> , 2018 , 50, 653-660	3.3	14
40	The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. <i>Digestive and Liver Disease</i> , 2018 , 50, 675-681	3.3	22
39	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018 , 50, 1292-1298	3.3	11
38	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017 , 49, 338-358	3.3	34

37	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017 , 49, 604-617	3.3	34
36	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. <i>Journal of Infection</i> , 2017 , 74, 433-441	18.9	23
35	The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 233-243	4.5	96
34	Endoscopic rescue treatment in a pregnant ulcerative colitis patient with a severe colonic stricture: a conservative approach to bring the pregnancy to term. <i>Gastrointestinal Endoscopy</i> , 2017 , 86, 1183-1185	5.2	2
33	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 981-987	2.4	15
32	Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e31	2.4	29
31	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 175-184	5.4	6
30	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , 2017 , 97, 1-3	14.5	11
29	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017 , 49, 1298-1305	3.3	10
28	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF- α inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017 , 49, 157-162	3.3	3
27	Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists. <i>Journal of Crohns and Colitis</i> , 2017 , 11, 556-561	1.5	21
26	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. <i>Digestive and Liver Disease</i> , 2016 , 48, 1314-1317	3.3	4
25	Frequency of thiopurine methyltransferase mutation in patients of Mediterranean area with inflammatory bowel disease and autoimmune disorders. <i>Digestive and Liver Disease</i> , 2016 , 48, 1506-1509	3.3	6
24	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , 2016 , 151, 211-2	13.3	5
23	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2016 , 48, 360-70	3.3	29
22	Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 914	6.9	7
21	Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 913-24	1.5	21
20	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohns and Colitis</i> , 2016 , 10, 1451	1.5	7

19	Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. <i>Journal of Clinical Virology</i> , 2015 , 66, 103-6	14.5	9
18	Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. <i>New England Journal of Medicine</i> , 2015 , 372, 1104-13	59.2	304
17	The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. <i>Autoimmunity Reviews</i> , 2014 , 13, 751-5	13.6	59
16	Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2014 , 46, 969-73	3.3	58
15	Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2014 , 46, 963-8	3.3	36
14	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014 , 13, 822-30	13.6	63
13	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 9675-90	5.6	51
12	Patient and physician views on the quality of care in inflammatory bowel disease: results from SOLUTION-1, a prospective IG-IBD study. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1642-52	1.5	17
11	Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohns and Colitis</i> , 2014 , 8, 1217-21	1.5	38
10	Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2013 , 45, 986-91	3.3	33
9	Adalimumab in active ulcerative colitis: a "real-life" observational study. <i>Digestive and Liver Disease</i> , 2013 , 45, 738-43	3.3	57
8	Increased risk of pneumonia among patients with inflammatory bowel disease: a comparison between patients treated with biologic therapies and with conventional drugs. <i>Journal of Crohns and Colitis</i> , 2013 , 7, e405-6	1.5	4
7	Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 826-31	4.5	10
6	Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 30-5	6.9	253
5	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2011 , 43, 1-20	3.3	101
4	Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 758-66	4.5	33
3	Gastrointestinal lesions associated with spondyloarthropathies. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2443-8	5.6	36
2	Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. <i>American Journal of Gastroenterology</i> , 2009 , 104, 514-24	0.7	199

- 1 Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. *Gastroenterology*, **2008**, 135, 1500-9 133 72